Association of immune-related adverse events with survival in patients receiving immune checkpoint inhibitor plus chemotherapy for lung cancer - PubMed
5 hours ago
- #survival analysis
- #immune checkpoint inhibitors
- #lung cancer
- The study investigates how immune-related adverse events (irAEs) are linked to survival in lung cancer patients treated with a combination of immune checkpoint inhibitors and chemotherapy.
- It involves the use of specific drugs like Atezolizumab and Pembrolizumab for non-small cell lung cancer.
- Several authors have declared financial relationships with pharmaceutical companies, which may present potential conflicts of interest.
- The research references recent cancer statistics and prior studies on immunotherapy combinations in lung cancer treatments.
- Findings may help in understanding the clinical benefits associated with irAEs, such as skin reactions, during immunotherapy.